Incyte changes manufacturing process, adds second site to solve Opzelura texture issue
From the start of Incyte’s Q1 earnings call, the manufacturing issues surrounding Opzelura were addressed by Hervé Hoppenot, the company’s CEO. And though issues have slowed the treatment back, the pharma said it added a second manufacturing site to produce the atopic dermatitis drug, and implemented a new process after gaining FDA approval.
“Consistent with best practices, we have received FDA approval for a second manufacturer of Opzelura to support our successful launch,” he said, before handing things over to US general manager Barry Flannelly. “We are also preparing to reintroduce samples in the US.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.